When was Oculeve founded?

Oculeve was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is Oculeve located?

Oculeve is headquartered in San Francisco, United States.

How many employees does Oculeve have?

As of May 31, 2026, the latest employee count at Oculeve is 2.

Is Oculeve a funded company?

Oculeve is a funded company, having raised a total of $24.9M across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2010.

When was the latest funding round of Oculeve?

Oculeve's latest funding was a $***** Series B round on Mar 18, 2014, with participation from 0 investor. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $1.15B in funding in 2026 to date.

Where does Oculeve rank among its competitors?

Oculeve ranks 1st amongst 24 active competitors, of which 2 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was TearRestore, which secured $500K in May, 2020.

Who are the top competitors of Oculeve?

Oculeve's top competitors include Tear Film Innovations, TearScience and Bruder Healthcare. Among them, TearRestore secured the most recent funding round in May, 2020.

Oculeve - 2026 Company Profile, Funding & Competitors

Q: Is Oculeve an acquired company?

Oculeve got acquired by Allergan on Jul 06, 2015.

Oculeve is an acquired company based in San Francisco (United States), founded in 2011. It operates as a Device for dry eye disease. Oculeve has raised $24.9M in funding. The company has 24 active competitors, including 2 funded and 6 that have exited. Its top competitors include companies like Tear Film Innovations, TearScience and Bruder Healthcare.

Company Details

Oculeve is developing a treatment for dry eye disease. Its technology was conceptualized at Stanford University in a collaboration between the Departments of Biodesign and Ophthalmology. Its lead product is a non-invasive nasal neurostimulation device that increases tear production in patients with dry eye disease. The company was acquired by Allergan in July 2015 for a $125M upfront payment and milestone payments related to its lead development program.

Key Metrics

Founded Year

2011

Location

San Francisco, United States

Stage

Acquired

Total Funding

$24.9M in 4 rounds

Latest Funding Round

Series B, Mar 18, 2014, $*****

Investors

Versant Ventures & 4 more

Ranked

1^st among 24 active competitors

Employee Count

2 as on May 31, 2026

Similar Companies

Tear Film Innovations & 26 more

Exit Details

Acquired by Allergan (Jul 06, 2015)

View Oculeve's full profile

Oculeve is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Oculeve, Inc. CIN: 453124046 , United States, Active	Dec 31, 1999	-	19 (As on Dec 31, 2015)	-

Oculeve got acquired by Allergan on Jul 06, 2015 at an acquisition amount of $*****.

Click here to take a look at Oculeve's acquisition in detail

Oculeve has raised a total funding of $24.9M over 4 rounds. Its first funding round was on 2010. Oculeve has 5 institutional investors.

Here is the list of recent funding rounds of Oculeve:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 18, 2014	9413988	Series B	5209703	2285074	8052427	5367153
Mar 20, 2013	5320176	Series A	4339128	6719512	1316464	New Enterprise Associates & 2 more
Aug 30, 2012	1395209	Seed	1461715	5146159	4138280	7978464

Access funding benchmarks and valuations. Sign up today!

View details of Oculeve's funding rounds and investors

Oculeve's employee count trend

Oculeve has 2 employees as of May 26. Here is Oculeve's employee count trend over the years:

Uncover Oculeve's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oculeve include Tear Film Innovations, TearScience and Bruder Healthcare. Here is the list of Top 10 competitors of Oculeve, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Oculeve 2011, San Francisco (United States), Acquired	Device for dry eye disease	$24.9M	Versant Ventures, Kleiner Perkins & 3 others	47/100
2nd	Tear Film Innovations 2012, San Diego (United States), Acquired	Device to stimulate and produce tears from the meibomian glands to treat evaporative dry-eye	$17.7M	Visionary Ventures, Tigris Ventures & 2 others	41/100
3rd	TearScience 2005, Morrisville (United States), Acquired	Innovating eye health solutions for a lifetime of clear vision	$151M	eneralcatalyst.com, Quaker Partners Management ... & 7 others	41/100
4th	Bruder Healthcare 1986, Alpharetta (United States), Acquired	Products for dry eye and pain management	$5.17M	Greybrook, Fulcrum Equity Partners	40/100
5th	Sinopsys Surgical 2011, Boulder (United States), Deadpooled	Lacrimal stent and procedure to treat sinusitis	$9.57M	Mercury Fund, High Country Ventures & 3 others	30/100
6th	EyeGiene 2010, Danville (United States), Unfunded	Device for the treatment of dry eyes	-	-	30/100
7th	Tsubota Lab 2015, Shinjuku City (Japan), Public	Developer of medical device for treating myopia, dry eye, and presbyopia	-	Keio Innovation Initiative	29/100
8th	Olympic Ophthalmics 2020, Issaquah (United States), Funding Raised	Provider and developer of tear production device for treatments of dry eye disease	-	Saints Capital, BioStar Capital & 1 others	28/100
9th	Eyedetec Medical 2007, Danville (United States), Funding Raised	Reimagining chronic dry eye therapy with innovative, affordable, and effective solutions	-	Octane	28/100
10th	TearRestore 2016, Minneapolis (United States), Seed	Provider of at-home dry eye treatment solutions. It offers clinically-proven products to relieve eye irritation and restore natural moisture. These solutions include eyelid cleansers, warm compresses, and eyelid serum, all designed for convenient and effective at-home use. The company aims to provide long-term eye health management through preventative care. Products are developed to address the root cause of dry eye, such as Meibomian Gland Dysfunction (MGD), by alleviating blocked oil glands and promoting tear film stability.	$500K	-	27/100